June 2008 Volume 4, Issue 6
Volume 4, Issue 6 | June 2008
June 2008
In this Issue
Informatics
One-stop data shop
LabVantage, InforSense integrate data management and analytics platformsFrom bedside to bench
GenoLogics develops translational research software for Fred Hutchinson CenterBest of both worlds
ClinPhone and invivodata align ePRO solutionsParkinson’s research 2.0
The Parkinson’s Institute, 23andMe launch Web-based research initiativeThe fat cell syndicate
Entelos lends PhysioLab model to Pfizer diabetes consortiumResearch & Development
On their own again
Pfizer sells cholesterol therapy-focused Esperion TherapeuticsA midnight discovery
Minerva stumbles upon cancer therapy breakthroughProfit for non-profit
SFBR launches for-profit drug company focused on women’s health concernsUF compound lowers blood pressure
University of Florida researchers have identified a drug compound that may prevent tissue damage associated with cardiovascular disease, according to a study published in the May 1 edition of the American Heart Association journal Hypertension.A one-two diabetes punch
DiaKine and Kinexum to develop novel combo treatment for type 1 diabetesGlobal News
BMS to buy Kosan for $190M
BMS enhances cancer portfolio in two important anti-cancer classesTakeda strikes deal with Alnylam
Non-exclusive platform deal could eventually net Alnylam $1 billionProtecting your genome
Congress passes and president signs genetic antidiscrimination billGenomics & Proteomics
Cancer cohorts
Researchers around the world launch the International Cancer Genome ConsortiumYerkes’ monkey business
Researchers develop first transgenic nonhuman primate model of Huntington’s diseaseOligo-ing above and beyond
Agilent and Broad team up on genome-partitioning kitsLipid mania
Lipidoids offer novel RNAi therapy deliveryHope springs eternal for Benitec’s IP
City of Hope trial helps Benitec to rebuild its RNAi strengthEditor's Focus
Strange bedfellows: Bill Gates and Chairman Mao
News recently out of a discussion at the The Royal Society, London, is raising hopes that an effective and affordable cure for malaria is now on the horizon. But what do both Bill Gates and Chairman Mao have to do with this story? Well, plenty, if you follow the thread and history of malaria treatments.Patent News
Is it difficult to do deals with universities?
Like many things in life, it’s always easy to criticize the other side. So, what is true?Commentary
Today’s biopharma venture capital challenge: Risk-sharing models versus risk avoidance
In times like these, when the pendulum of fear swings to risk avoidance, biopharma can only develop products that meet both customer needs and Wall Street expectations through innovative, novel product development based on a reconsidered approach to risk management.Feature
Trials and tribulations
Effective recruiting for clinical trials requires a commitment to educating patients and physiciansAutomation & Instrumentation
Geared up for GPCRs
DiscoveRx, Caliper team up on microfluidic, cell-based assay deal targeting GPCR researchersPutting their ChIPs on the table
Illumina, Genpathway team up to offer whole-genome ChIP sequencing servicesInvitrogen intros cell therapy biz unit
Invitrogen Corp., which has been steadily building its cell therapy expertise, announced in mid-May the formation of a separate cell therapy business unit focused on the specific needs of the clinical cell therapy market.Promega and GeneCopoeia play tag
Companies combine HaloTag with human and mouse ORF sequences
Subscribe to our eNewsletters
Stay connected with all of the latest from Drug Discovery News.
SubscribeSponsored
Harnessing liver-on-a-chip models for drug safety
Discover how researchers leverage microphysiological systems in toxicology studies.
Enhancing bioanalytical studies with centralized data management
Learn how researchers can improve compliance and efficiency with advanced LIMS solutions.
Explained: How are metabolite biomarkers improving drug discovery and development?
By offering a rich source of insights into disease and drugs, metabolite biomarkers are at the forefront of therapeutic exploration.
